Top Page
Microbix Biosystms
(TSX:MBX)
Microbix Biosystms (MBX) vs. iShares MSCI Canada ETF (EWC)
Microbix Biosystms Business Overview & Revenue Model
Microbix Biosystms Earnings Call Summary
Microbix Biosystms Financial Statement Overview
| Breakdown | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 25.39M | 16.51M | 19.08M | 18.59M | 10.52M |
| Gross Profit | 15.39M | 7.48M | 11.12M | 11.04M | 4.66M |
| EBITDA | 6.21M | 1.96M | 3.73M | 5.66M | -2.91M |
| Net Income | 3.52M | -39.48K | 1.79M | 1.63M | -6.23M |
Balance Sheet | |||||
| Total Assets | 38.10M | 35.65M | 33.15M | 28.83M | 15.60M |
| Cash, Cash Equivalents and Short-Term Investments | 12.96M | 11.61M | 13.49M | 9.99M | 92.66K |
| Total Debt | 6.40M | 6.65M | 5.82M | 7.74M | 6.17M |
| Total Liabilities | 9.80M | 11.03M | 8.21M | 10.27M | 8.98M |
| Stockholders Equity | 28.30M | 24.62M | 24.94M | 18.56M | 6.62M |
Cash Flow | |||||
| Free Cash Flow | 2.44M | -2.11M | 1.44M | 804.20K | -805.34K |
| Operating Cash Flow | 4.35M | -1.09M | 3.47M | 2.11M | 8.57K |
| Investing Cash Flow | -1.91M | -1.02M | -2.03M | -622.34K | -813.91K |
| Financing Cash Flow | -1.08M | 229.21K | 2.06M | 8.41M | 802.43K |
Microbix Biosystms Technical Analysis
Microbix Biosystms Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | C$69.09M | 17.91 | 14.51% | ― | 28.97% | ― | |
65 Neutral | ¥341.81B | 11.08 | -0.17% | 2.40% | 9.51% | -9.51% | |
60 Neutral | C$34.31M | 24.14 | -1.13% | ― | -9.54% | -105.12% | |
| ― | $93.74M | ― | -244.84% | ― | ― | ― | |
43 Neutral | C$52.32M | ― | ― | -33.66% | -48.89% | ||
33 Underperform | C$64.05M | ― | 248.46% | ― | ― | 49.34% | |
33 Underperform | C$90.47M | ― | 685.26% | ― | ― | -31.12% |
Microbix Biosystms Corporate Events
Microbix Biosystems reported a challenging third quarter for fiscal 2025, with revenues falling to $3.5 million, a 31% decrease from the previous year, primarily due to reduced sales in China and the cancellation of test-development programs by a key customer. Despite a strong cash position, the company experienced a net loss of $1.64 million, driven by weaker gross margins and increased operating expenses. The year-to-date performance also saw a decline in revenues and margins, leading to an operating loss, although antigen sales showed some growth. The company’s financial ratios improved, indicating a strong liquidity position, but the outlook remains cautious due to ongoing challenges in key markets.
The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.80 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Microbix Biosystems Inc. announced the upcoming release of its Q3 fiscal 2025 financial results, scheduled for August 14, 2025, followed by a webinar discussion with the company’s executives. This announcement is significant for stakeholders as it provides insights into the company’s financial health and operational performance, potentially impacting its market positioning and investor confidence.
The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.80 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Microbix Biosystems Inc. has launched QUANTDx™, a new line of characterized reference materials aimed at supporting diagnostic assay manufacturers. This product line, introduced at the ADLM 2025 conference, includes over 80 reference materials covering six common disease panels, addressing a critical need for high-quality, standardized materials in infectious disease diagnostics. The launch is expected to enhance Microbix’s role as a trusted partner in the diagnostics industry, drive revenue growth, and expand its global customer base.
The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.80 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Microbix Biosystems Inc. announced its participation in the Association for Diagnostic & Laboratory Medicine (ADLM) conference in Chicago, where it will present and exhibit its quality assessment products (QAPs) that ensure the accuracy of diagnostic tests. A key highlight is the presentation of a pilot External Quality Assessment program using novel QAPs for detecting the H5N1 pandemic strain, developed in collaboration with the American Proficiency Institute. This initiative underscores Microbix’s role in pandemic preparedness, showcasing its ability to rapidly deploy solutions for emerging health threats.
The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.80 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Microbix Biosystems Inc. has entered into a multi-year agreement with Bulgaria’s National Center for Infectious and Parasitic Diseases (NCIPD) to develop new quality assessment products (QAPs) using pathogen seedstocks supplied by NCIPD. This collaboration aims to enhance the accuracy of diagnostic tests for infectious diseases, thereby improving global health outcomes. The agreement will allow Microbix to expand its portfolio of QAPs, leveraging NCIPD’s extensive collection of characterized microorganisms. This strategic partnership is expected to strengthen Microbix’s position in the diagnostics industry by increasing its product offerings and supporting the accuracy of emerging tests for bacterial, parasitic, and viral infections.
The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.80 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Microbix Biosystems Inc. announced its participation in the Asia Pacific Conference on Point of Care Testing for Infectious Diseases in Bangkok, where it will present its quality assessment products (QAPs) that support point-of-care testing. The company will showcase its innovations that ensure diagnostic test accuracy, particularly for infectious diseases relevant to the Asia Pacific region. The presentation will highlight the robust performance of Microbix’s QAPs, which have been crucial in supporting SARS-CoV-2 tests and contributed to the company’s selection as a key quality control device partner in the EPICC initiative for HPV elimination. This engagement is expected to enhance Microbix’s role in point-of-care testing programs and expand its collaborations with diagnostics manufacturers.
The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.80 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Microbix Biosystems reported its Q2 fiscal 2025 results, showing a revenue of $5.3 million, a slight decrease from the previous year, but with improved gross margins. The company experienced growth in antigen sales, offset by a decline in QAPs due to delays with a major customer. Despite increased operating expenses, Microbix achieved a positive net income and improved financial strength, with strong cash reserves and liquidity. However, the outlook for the second half of fiscal 2025 is cautious due to reduced sales in China, impacting the company’s future growth prospects.
The most recent analyst rating on (TSE:MBX) stock is a Buy with a C$0.80 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.